More importantly, we performed a screen and identified a SCARB2 binding molecule, PMB, which is a clinically available polymyxin antibiotic that has re-emerged clinically to treat infections caused by multidrug- or extensively drug-resistant gram-negative bacteria. Here, SCARB2 is linked to infection.